Ionis Exceeds 2018 Financial Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. KTOS
4. PLTR
5. SPY
6. AON
7. TMUS
8. LBRX
9. BMY
10. MRK

Go back to Ionis Exceeds 2018 Financial Guidance

Ionis Pharmaceuticals (IONS) Reports Q4 EPS of $2.21, Revenues Beat

February 27, 2019 7:14 AM EST

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of $2.21, versus ($0.03) reported last year. Revenue for the quarter came in at $192.11 million versus the consensus estimate of $170.89 million.

"We begin 2019 in the strongest position in our 30-year history. Building on this foundation, we believe we are positioned for continued growth," said Stanley T. Crooke, M.D., Ph.D., chairman of the board and chief executive officer of Ionis. "In 2018, we launched TEGSEDI globally through our affiliate, Akcea, adding revenue from TEGSEDI sales to our substantial commercial revenue from SPINRAZA. We also... More